Boehringer Ingelheim and MD Anderson Cancer Center join forces to discover new treatment approaches for pancreatic cancer

● Pancreatic ductal adenocarcinoma is one of the most lethal of cancers with no effective treatments    available ● Boehringer Ingelheim and MD Anderson Cancer Center to identify new therapeutic concepts,    biomarkers and develop breakthrough medicines to treat pancreatic cancer ● This collaboration underscores Boehringer Ingelheim’s focus on difficult-to-treat diseases and    commitment to precision medicines
Source: Boehringer Ingelheim Press Releases - Category: Research Source Type: news